Medikamentöse Therapie des Kolonkarzinoms

Schlüsselwörter

Kolonkarzinom - neoadjuvante, adjuvante, palliative Chemotherapie - medikamentöse Tumortherapie

Key words

colon cancer - neoadjuvant, adjuvant, palliative chemotherapy - pharmacotherapy of cancer

Literatur

• 1 Advanced Colorectal Cancer Meta-Analysis Project . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate.  J Clin Oncol. 1992;  10 896-903
• 2 Alberts S R, Horvath W L, Sternfeld W C. et al . Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer.  J Clin Oncol. 2005;  23 9243-9249
• 3 Andre T, Boni C, Mounedji-Boudiaf L. et al . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  350 2343-2351
• 4 Ardalan B, Chua L, Tian E M. et al . A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.  J Clin Oncol. 1991;  9 625-630
• 5 Benoist S, Brouquet A, Penna C. et al . Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.  J Clin Oncol. 2006;  24 3939-3945
• 6 Cassidy J, Twelves C, Van Cutsem E. et al . First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.  Ann Oncol. 2002;  13 566-575
• 7 de Gramont A, Figer A, Seymour M. et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2947
• 8 Deutschland AbKi .Krebs in Deutschland - Häufigkeiten und Trends. 5. erweiterte, aktualisierte Auflage 2006: 14-15
• 9 Douillard J Y, Cunningham D, Roth A D. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer.  Lancet. 2000;  355 1041-1047
• 10 Douillard J Y, Hoff P M, Skillings J R. et al . Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.  J Clin Oncol. 2002;  20 3605-3616
• 11 Falcone A, Ricci S, Brunetti I. et al . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer.  J Clin Oncol. 2007;  25 1670-1676
• 12 Folprecht G, Grothey A, Alberts S, Raab H R, Kohne C H. Neoadjuvant treatment of unresectable colorectal liver metastases.  Ann Oncol. 2005;  16 1311-1319
• 13 Fong Y, Fortner J, Sun R L, Brennan M F, Blumgart L H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer.  Annals of surgery. 1999;  230 309-318
• 14 Giacchetti S, Itzhaki M, Gruia G. et al . Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.  Ann Oncol. 1999;  10 663-669
• 15 Giantonio B J. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.  Seminars in oncology. 2006;  33 S15-18
• 16 Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden P O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer.  Cancer. 1994;  73 556-562
• 17 Goldberg R M, Sargent D J, Morton R F. et al . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.  J Clin Oncol. 2004;  22 23-30
• 18 Goldberg R M, Tabah-Fisch I, Bleiberg H. et al . Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.  J Clin Oncol. 2006;  24 4085-4091
• 19 Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.  J Clin Oncol. 2005;  23 9441-9442
• 20 Group Q C. QUASAR Collaborative Group . Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer.  Lancet. 2000;  355 1588-1596
• 21 Hoff P M, Ansari R, Batist G. et al . Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer.  J Clin Oncol. 2001;  19 2282-2292
• 22 Hurwitz H, Fehrenbacher L, Novotny W. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 23 Kabbinavar F F, Hambleton J, Mass R D. et al . Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.  J Clin Oncol. 2005;  23 3706-3712
• 24 Karoui M, Penna C, Amin-Hashem M. et al . Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.  Annals of surgery. 2006;  243 1-7
• 25 Kohne C H, Cunningham D, Di C F. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer.  Ann Oncol. 2002;  13 308-317
• 26 Kohne C H, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer.  Ann Oncol. 2001;  12 435-442
• 27 Kohne C H, Wils J, Lorenz M. et al . Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer.  J Clin Oncol. 2003;  21 3721-3728
• 28 Kopec J A, Yothers G, Ganz P A. et al . Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy.  J Clin Oncol. 2007;  25 424-430
• 29 Lembersky B C, Wieand H S, Petrelli N J. et al . Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon.  J Clin Oncol. 2006;  24 2059-2064
• 30 Lokich J J, Ahlgren J D, Gullo J J, Philips J A, Fryer J G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma.  J Clin Oncol. 1989;  7 425-432
• 31 Maindrault-Goebel F, Louvet C, Andre T. et al . Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.  Eur J Cancer. 1999;  35 1338-1342
• 32 Maindrault-Goebel F, Tournigand C, Andre T. et al . Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.  Ann Oncol. 2004;  15 1210-1214
• 33 Maughan T S, James R D, Kerr D J. et al . Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer.  Lancet. 2003;  361 457-464
• 34 Moertel C G, Fleming T R, Macdonald J S. et al . Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma.  Ann Intern Med. 1995;  122 321-326
• 35 Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer.  J Clin Oncol. 1992;  10 904-911
• 36 Nuzzo G, Giuliante F, Ardito F. et al . Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.  J Gastrointest Surg. 2007;  11 318-324
• 37 Poplin E A, Benedetti J K, Estes N C. et al . Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.  J Clin Oncol. 2005;  23 1819-1825
• 38 Porschen R, Arkenau H T, Kubicka S. et al . Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin: A Randomized Comparison in Metastatic Colorectal Cancer - A Final Report of the AIO Colorectal Study Group.  J Clin Oncol. 2007;  E-Pub Jul 11
• 39 Portier G, Elias D, Bouche O. et al . Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases.  J Clin Oncol. 2006;  24 4976-4982
• 40 Poston G J, Adam R, Alberts S. et al . OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.  J Clin Oncol. 2005;  23 7125-7134
• 41 Saltz L B, Niedzwiecki D, Hollis D. et al . Irinotecan Fluorouracil plus Leucovorin is not superior to Fluorouracil plus Leucovorin alone as adjuvant treatment for stage III colon cancer.  JCO. 2007;  25 3456-3461
• 42 Rougier P, Van Cutsem E, Bajetta E. et al . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.  Lancet. 1998;  352 1407-1412
• 43 Saltz L B, Cox J V, Blanke C. et al. Irinotecan Study Group . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2000;  343 905-914
• 44 Saltz L B, Meropol N J, Loehrer P J. et al . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.  J Clin Oncol. 2004;  22 1201-1208
• 45 Sargent D J, Goldberg R M, Jacobson S D. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
• 46 Sargent D J, Niedzwiecki D, O’Connell M J, Schilsky R L. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.  N Engl J Med. 2001;  345 144-145 , ; author reply 146
• 47 Scappaticci F A, Fehrenbacher L, Cartwright T. et al . Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.  Journal of surgical oncology. 2005;  91 173-180
• 48 Scheithauer W, Rosen H, Kornek G V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  BMJ. 1993;  306 752-755
• 49 Schmoll H J, Cartwright T, Tabernero J. et al . Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.  J Clin Oncol. 2007;  25 102-109
• 50 Tournigand C, Andre T, Achille E. et al . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.  J Clin Oncol. 2004;  22 229-237
• 51 Twelves C, Wong A, Nowacki M P. et al . Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 2696-2704
• 52 Van Cutsem E, Douillard J Y, Kohne C H. Toxicity of irinotecan in patients with colorectal cancer.  N Engl J Med. 2001;  345 1351-1352
• 53 Van Cutsem E, Peeters M, Siena S. et al . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.  J Clin Oncol. 2007;  25 1658-1664
• 54 Van Cutsem E, Twelves C, Cassidy J. et al . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer.  J Clin Oncol. 2001;  19 4097-4106
• 55 Vauthey J N, Pawlik T M, Ribero D. et al . Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
• 56 Welsh F K, Tilney H S, Tekkis P P, John T G, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing.  British journal of cancer. 2007;  96 1037-1042